Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WELCHOL vs KYXATA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.
Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).
Primary hyperlipidemia (Fredrickson type IIa and IIb) as monotherapy or in combination with an HMG-Co A reductase inhibitor (statin) to reduce LDL-C,Adjunctive therapy for heterozygous familial hypercholesterolemia in pediatric patients aged 10-17 years,Improvement of glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
Pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise capacity and delay clinical worsening,Treatment of PAH in combination with other PAH therapies
Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.
KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.
Not applicable; colesevelam acts locally in the gastrointestinal tract and is not absorbed systemically. Terminal half-life is not measurable in conventional pharmacokinetic sense due to negligible systemic absorption.
Terminal elimination half-life is 12–15 hours in adults with normal renal function; extends to 22–30 hours in moderate renal impairment (Cr Cl 30–50 m L/min) and up to 48 hours in severe impairment (Cr Cl <30 m L/min).
Colesevelam is not absorbed systemically and therefore not metabolized by hepatic cytochrome P450 enzymes. It acts locally in the gastrointestinal tract and is excreted unchanged in the feces.
Primarily hepatic via CYP3A4 and CYP2C19; minor contribution from UGT1A1, UGT1A3, UGT1A9. Active metabolite (M14) via dealkylation.
Primarily fecal as unchanged drug (approximately 85%), with less than 0.5% renal excretion of absorbed drug; no biliary excretion due to non-absorbed nature.
Renal excretion accounts for approximately 70% of elimination (60% unchanged, 10% as metabolites); biliary/fecal excretion accounts for 25% (primarily as metabolites); minor metabolic clearance (5%) via CYP3A4.
<0.1% (negligible systemic absorption results in minimal protein binding; colesevelam is a non-absorbed polymer).
88–92% bound to albumin and alpha-1-acid glycoprotein.
Not applicable (colesevelam is not systemically absorbed; Vd cannot be determined and is clinically irrelevant).
0.8–1.2 L/kg, indicating extensive extravascular distribution into tissues including brain and myocardium.
Oral bioavailability <0.5% (negligible systemic absorption); drug acts locally in gastrointestinal tract.
Oral: 35–45% (due to first-pass metabolism); IM: 80–90%; IV: 100%.
No dose adjustment needed for renal impairment.
No dosage adjustment is required for renal impairment. Landiolol is minimally renally excreted (approximately 1% unchanged). However, use caution in patients with severe renal impairment (Cr Cl < 30 m L/min) due to limited data.
Not recommended in patients with bowel obstruction or severe hepatic impairment; no specific Child-Pugh guidelines.
For mild hepatic impairment (Child-Pugh Class A): No dosage adjustment needed. For moderate to severe hepatic impairment (Child-Pugh Class B or C): Reduce initial infusion rate to 0.05 mg/kg/min and titrate cautiously; maximum infusion rate of 0.2 mg/kg/min is recommended due to reduced clearance.
Not approved for use in pediatric patients.
Weight-based dosing: Loading dose of 0.125 mg/kg intravenously over 1 minute, followed by continuous infusion starting at 0.05 mg/kg/min, titrated to effect. Maximum infusion rate is 0.3 mg/kg/min. Safety and efficacy established in pediatric patients aged 1 to <18 years.
No specific dose adjustment; use with caution due to potential constipation.
Elderly patients (≥65 years): Start at the lower end of the dosing range (initial infusion rate of 0.05 mg/kg/min) and titrate slowly due to potential decreased hepatic function and increased sensitivity. No specific dose adjustment mandated, but monitor heart rate and blood pressure closely.
None
Embryofetal toxicity: Must be avoided in pregnancy; females of reproductive potential must use reliable contraception and have monthly pregnancy tests.
May increase serum triglycerides; use with caution in patients with hypertriglyceridemia, particularly when triglyceride levels exceed 300 mg/d L, as it may cause severe hypertriglyceridemia and pancreatitis.,May decrease absorption of fat-soluble vitamins (A, D, E, K) and folic acid; monitor and consider supplementation if necessary.,May cause gastrointestinal adverse effects such as constipation, dyspepsia, and abdominal pain; patients should be advised to increase fluid and fiber intake.,May reduce absorption of orally administered drugs; administer other medications at least 4 hours before Welchol or consider separating by longer intervals.,Use with caution in patients with swallowing disorders or gastrointestinal motility disorders.,Not recommended for patients with pre-existing hypertriglyceridemia (triglycerides >500 mg/d L) due to risk of severe elevation.
Hepatotoxicity (requires monthly liver function monitoring); fluid retention (peripheral edema, may require diuretics); hematologic changes (hemoglobin decrease, requires periodic monitoring); pulmonary veno-occlusive disease (PVOD) should be excluded.
History of hypersensitivity to colesevelam or any component of the formulation,Bowel obstruction,Serum triglyceride level >500 mg/d L
Pregnancy (absolute); hypersensitivity to macitentan or any component; concomitant use with strong CYP3A4 inducers (e.g., rifampin) (relative); severe hepatic impairment (Child-Pugh C) (relative).
Take with meals to enhance binding of bile acids. Avoid high-fat meals if triglycerides elevated. No specific food restrictions beyond general healthy diet.
Avoid alcohol and grapefruit juice. High-fat meals may delay absorption; take on empty stomach for consistent effect.
Welchol (colesevelam) is a bile acid sequestrant. In animal studies, no evidence of teratogenicity was observed at doses up to 3 times the human dose. Human data are limited. The drug is not absorbed systemically, so fetal exposure is negligible. However, it may reduce absorption of fat-soluble vitamins (A, D, E, K), which are essential for fetal development. Insufficient vitamin K can cause neonatal coagulopathy. Therefore, potential risk of fetal harm is low but theoretical if maternal vitamin deficiency occurs. FDA Pregnancy Category B.
No human data; animal studies not available. Risk cannot be excluded; avoid in pregnancy unless benefit outweighs potential fetal risk.
Colesevelam is not absorbed systemically and is not expected to be excreted into breast milk. No human studies are available. The M/P ratio is unknown but likely extremely low due to lack of absorption. Caution is advised, but risk to nursing infant is minimal. Monitor infant for signs of vitamin deficiency if mother is on long-term therapy.
No human data; M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise against breastfeeding during therapy.
No pharmacokinetic changes are reported for colesevelam in pregnancy as it is not absorbed. Standard dosing may be used, but ensure adequate supplementation of fat-soluble vitamins, especially vitamins A, D, E, and K. Dose adjustments are not required based on pregnancy status alone. Monitor for constipation, which may be exacerbated in pregnancy.
No pharmacokinetic data in pregnancy; no dose adjustment guidelines available. Use with caution and therapeutic drug monitoring if applicable.
Administer Welchol at least 4 hours after other medications to avoid binding and reducing absorption. Monitor LDL-C reduction at 4-6 weeks; may increase triglycerides. Contraindicated in history of hypertriglyceridemia-induced pancreatitis.
KYXATA (potassium oxyrate) is a CNS depressant; avoid concurrent use with alcohol or other sedatives. Monitor for respiratory depression, especially in elderly or COPD patients. Taper dose to prevent withdrawal seizures. Not a controlled substance but carries abuse potential.
Take Welchol with a meal and plenty of water.,Take other medications at least 4 hours before or after Welchol.,Do not crush or chew the tablets; swallow whole.,May cause constipation; increase fluid and fiber intake.,Report severe stomach pain or triglyceridemia symptoms.
Take exactly as prescribed; do not increase dose or frequency.,Avoid driving or operating machinery until you know how KYXATA affects you.,Do not drink alcohol while taking this medication.,Do not stop suddenly; abrupt discontinuation may cause seizures.,Report any unusual changes in mood, thoughts, or behavior.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WELCHOL vs KYXATA, answered by our medical review team.
WELCHOL is a Bile Acid Sequestrant that works by Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.. KYXATA is a Unknown that works by Selective endothelin receptor antagonist (ERA) targeting endothelin type A (ETA) receptors, reducing pulmonary vascular resistance and remodeling in pulmonary arterial hypertension (PAH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WELCHOL and KYXATA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WELCHOL is: Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.. The standard adult dose of KYXATA is: KYXATA (landiolol) intravenously: For atrial fibrillation/flutter (AF/AFL) with rapid ventricular rate: Initial intravenous bolus dose of 0.125 mg/kg over 1 minute, followed by continuous intravenous infusion of 0.05 to 0.2 mg/kg/min, titrated to heart rate control. Maximum infusion rate is 0.4 mg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WELCHOL and KYXATA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WELCHOL is classified as Category C. Welchol (colesevelam) is a bile acid sequestrant. In animal studies, no evidence of teratogenicity was observed at doses up to 3 times the human dose. Human data are limited. The d. KYXATA is classified as Category C. No human data; animal studies not available. Risk cannot be excluded; avoid in pregnancy unless benefit outweighs potential fetal risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.